Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer.

Weisner J, Landel I, Reintjes C, Uhlenbrock N, Trajkovic-Arsic M, Dienstbier N, Hardick J, Ladigan S, Lindemann M, Smith S, Quambusch L, Scheinpflug R, Depta L, Gontla R, Unger A, Müller H, Baumann M, Schultz-Fademrecht C, Günther G, Maghnouj A, Müller MP, Pohl M, Teschendorf C, Wolters H, Viebahn R, Tannapfel A, Uhl W, Hengstler JG, Hahn SA, Siveke JT, Rauh D.

Cancer Res. 2019 May 1;79(9):2367-2378. doi: 10.1158/0008-5472.CAN-18-2861. Epub 2019 Mar 11.

PMID:
30858154
2.

A Novel Approach for Image-Guided 131I Therapy of Pancreatic Ductal Adenocarcinoma Using Mesenchymal Stem Cell-Mediated NIS Gene Delivery.

Schug C, Gupta A, Urnauer S, Steiger K, Cheung PF, Neander C, Savvatakis K, Schmohl KA, Trajkovic-Arsic M, Schwenk N, Schwaiger M, Nelson PJ, Siveke JT, Spitzweg C.

Mol Cancer Res. 2019 Jan;17(1):310-320. doi: 10.1158/1541-7786.MCR-18-0185. Epub 2018 Sep 17.

PMID:
30224540
3.

Notch-Induced Myeloid Reprogramming in Spontaneous Pancreatic Ductal Adenocarcinoma by Dual Genetic Targeting.

Cheung PF, Neff F, Neander C, Bazarna A, Savvatakis K, Liffers ST, Althoff K, Lee CL, Moding EJ, Kirsch DG, Saur D, Bazhin AV, Trajkovic-Arsic M, Heikenwalder MF, Siveke JT.

Cancer Res. 2018 Sep 1;78(17):4997-5010. doi: 10.1158/0008-5472.CAN-18-0052. Epub 2018 May 29.

PMID:
29844119
4.

Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma.

Trajkovic-Arsic M, Heid I, Steiger K, Gupta A, Fingerle A, Wörner C, Teichmann N, Sengkwawoh-Lueong S, Wenzel P, Beer AJ, Esposito I, Braren R, Siveke JT.

Sci Rep. 2017 Dec 6;7(1):17038. doi: 10.1038/s41598-017-16826-z.

5.

Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene.

Schmohl KA, Gupta A, Grünwald GK, Trajkovic-Arsic M, Klutz K, Braren R, Schwaiger M, Nelson PJ, Ogris M, Wagner E, Siveke JT, Spitzweg C.

Oncotarget. 2017 May 16;8(20):33393-33404. doi: 10.18632/oncotarget.16499.

6.

Hes1 Controls Exocrine Cell Plasticity and Restricts Development of Pancreatic Ductal Adenocarcinoma in a Mouse Model.

Hidalgo-Sastre A, Brodylo RL, Lubeseder-Martellato C, Sipos B, Steiger K, Lee M, von Figura G, Grünwald B, Zhong S, Trajkovic-Arsic M, Neff F, Schmid RM, Siveke JT.

Am J Pathol. 2016 Nov;186(11):2934-2944. doi: 10.1016/j.ajpath.2016.07.025. Epub 2016 Sep 14.

PMID:
27639167
7.

Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer.

Heid I, Steiger K, Trajkovic-Arsic M, Settles M, Eßwein MR, Erkan M, Kleeff J, Jäger C, Friess H, Haller B, Steingötter A, Schmid RM, Schwaiger M, Rummeny EJ, Esposito I, Siveke JT, Braren RF.

Clin Cancer Res. 2017 Mar 15;23(6):1461-1470. doi: 10.1158/1078-0432.CCR-15-2432. Epub 2016 Sep 23.

8.

Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.

Mazur PK, Herner A, Mello SS, Wirth M, Hausmann S, Sánchez-Rivera FJ, Lofgren SM, Kuschma T, Hahn SA, Vangala D, Trajkovic-Arsic M, Gupta A, Heid I, Noël PB, Braren R, Erkan M, Kleeff J, Sipos B, Sayles LC, Heikenwalder M, Heßmann E, Ellenrieder V, Esposito I, Jacks T, Bradner JE, Khatri P, Sweet-Cordero EA, Attardi LD, Schmid RM, Schneider G, Sage J, Siveke JT.

Nat Med. 2015 Oct;21(10):1163-71. doi: 10.1038/nm.3952. Epub 2015 Sep 21.

9.

Selective in vivo imaging of syngeneic, spontaneous, and xenograft tumors using a novel tumor cell-specific hsp70 peptide-based probe.

Stangl S, Varga J, Freysoldt B, Trajkovic-Arsic M, Siveke JT, Greten FR, Ntziachristos V, Multhoff G.

Cancer Res. 2014 Dec 1;74(23):6903-12. doi: 10.1158/0008-5472.CAN-14-0413. Epub 2014 Oct 9.

10.

FMT-PCCT: hybrid fluorescence molecular tomography-x-ray phase-contrast CT imaging of mouse models.

Mohajerani P, Hipp A, Willner M, Marschner M, Trajkovic-Arsic M, Ma X, Burton NC, Klemm U, Radrich K, Ermolayev V, Tzoumas S, Siveke JT, Bech M, Pfeiffer F, Ntziachristos V.

IEEE Trans Med Imaging. 2014 Jul;33(7):1434-46. doi: 10.1109/TMI.2014.2313405. Epub 2014 Mar 24.

PMID:
24686244
11.

Multimodal molecular imaging of integrin αvβ3 for in vivo detection of pancreatic cancer.

Trajkovic-Arsic M, Mohajerani P, Sarantopoulos A, Kalideris E, Steiger K, Esposito I, Ma X, Themelis G, Burton N, Michalski CW, Kleeff J, Stangl S, Beer AJ, Pohle K, Wester HJ, Schmid RM, Braren R, Ntziachristos V, Siveke JT.

J Nucl Med. 2014 Mar;55(3):446-51. doi: 10.2967/jnumed.113.129619. Epub 2014 Feb 18.

12.

Validation of heat shock protein 70 as a tumor-specific biomarker for monitoring the outcome of radiation therapy in tumor mouse models.

Bayer C, Liebhardt ME, Schmid TE, Trajkovic-Arsic M, Hube K, Specht HM, Schilling D, Gehrmann M, Stangl S, Siveke JT, Wilkens JJ, Multhoff G.

Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):694-700. doi: 10.1016/j.ijrobp.2013.11.008.

PMID:
24521683
13.

Monocarboxylate transporter 8 modulates the viability and invasive capacity of human placental cells and fetoplacental growth in mice.

Vasilopoulou E, Loubière LS, Heuer H, Trajkovic-Arsic M, Darras VM, Visser TJ, Lash GE, Whitley GS, McCabe CJ, Franklyn JA, Kilby MD, Chan SY.

PLoS One. 2013 Jun 12;8(6):e65402. doi: 10.1371/journal.pone.0065402. Print 2013.

14.

X-ray phase-contrast CT of a pancreatic ductal adenocarcinoma mouse model.

Tapfer A, Braren R, Bech M, Willner M, Zanette I, Weitkamp T, Trajkovic-Arsic M, Siveke JT, Settles M, Aichler M, Walch A, Pfeiffer F.

PLoS One. 2013;8(3):e58439. doi: 10.1371/journal.pone.0058439. Epub 2013 Mar 11.

15.

The role of insulin and IGF system in pancreatic cancer.

Trajkovic-Arsic M, Kalideris E, Siveke JT.

J Mol Endocrinol. 2013 Apr 23;50(3):R67-74. doi: 10.1530/JME-12-0259. Print 2013 Jun. Review.

PMID:
23493758
16.

Tetrac can replace thyroid hormone during brain development in mouse mutants deficient in the thyroid hormone transporter mct8.

Horn S, Kersseboom S, Mayerl S, Müller J, Groba C, Trajkovic-Arsic M, Ackermann T, Visser TJ, Heuer H.

Endocrinology. 2013 Feb;154(2):968-79. doi: 10.1210/en.2012-1628. Epub 2013 Jan 10.

PMID:
23307789
17.

EGF receptor is required for KRAS-induced pancreatic tumorigenesis.

Ardito CM, Grüner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, Delgiorno KE, Carpenter ES, Halbrook CJ, Hall JC, Pal D, Briel T, Herner A, Trajkovic-Arsic M, Sipos B, Liou GY, Storz P, Murray NR, Threadgill DW, Sibilia M, Washington MK, Wilson CL, Schmid RM, Raines EW, Crawford HC, Siveke JT.

Cancer Cell. 2012 Sep 11;22(3):304-17. doi: 10.1016/j.ccr.2012.07.024.

18.

MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancer.

Grüner BM, Hahne H, Mazur PK, Trajkovic-Arsic M, Maier S, Esposito I, Kalideris E, Michalski CW, Kleeff J, Rauser S, Schmid RM, Küster B, Walch A, Siveke JT.

PLoS One. 2012;7(6):e39424. doi: 10.1371/journal.pone.0039424. Epub 2012 Jun 26.

19.

Impact of monocarboxylate transporter-8 deficiency on the hypothalamus-pituitary-thyroid axis in mice.

Trajkovic-Arsic M, Müller J, Darras VM, Groba C, Lee S, Weih D, Bauer K, Visser TJ, Heuer H.

Endocrinology. 2010 Oct;151(10):5053-62. doi: 10.1210/en.2010-0593. Epub 2010 Aug 11.

PMID:
20702572
20.

Consequences of monocarboxylate transporter 8 deficiency for renal transport and metabolism of thyroid hormones in mice.

Trajkovic-Arsic M, Visser TJ, Darras VM, Friesema EC, Schlott B, Mittag J, Bauer K, Heuer H.

Endocrinology. 2010 Feb;151(2):802-9. doi: 10.1210/en.2009-1053. Epub 2009 Dec 8.

PMID:
19996182

Supplemental Content

Loading ...
Support Center